Clinical Trials · NCT05577728

Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

Phase
N/A
Recruitment status
Completed
Sponsor
Brigham and Women's Hospital
Enrollment
2,316
Start date
Jul 2021
Locations
1 site, United States
Primary endpoint
Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol)
View Semaglutide compound reference